Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
1.
Eur J Neurol ; 28(2): 389-400, 2021 02.
Article in English | MEDLINE | ID: mdl-33035386

ABSTRACT

BACKGROUND AND PURPOSE: Protein tyrosine phosphatase receptor type Q (PTPRQ) was extracted from the cerebrospinal fluid (CSF) of patients with probable idiopathic normal-pressure hydrocephalus (iNPH) by proteome analysis. We aimed to assess the feasibility of using CSF PTPRQ concentrations for the additional diagnostic criterion of iNPH in Japanese and Finnish populations. METHODS: We compared PTPRQ concentrations among patients with probable iNPH and neurologically healthy individuals (normal control [NC] group), patients with normal-pressure hydrocephalus (NPH) of acquired and congenital/developmental aetiologies, patients with Alzheimer's disease and patients with Parkinson's disease in a Japanese analysis cohort. A corresponding iNPH group and NC group in a Finnish cohort was used for validation. Patients in the Finnish cohort who underwent biopsy were classified into two groups based on amyloid and/or tau deposition. We measured PTPRQ expression levels in autopsied brain specimens of iNPH patients and the NC group. RESULTS: Cerebrospinal fluid PTPRQ concentrations in the patients with NPH of idiopathic, acquired and congenital/developmental aetiologies were significantly higher than those in the NC group and those with Parkinson's disease, but iNPH showed no significant differences when compared with those in the Alzheimer's disease group. For the patients with iNPH, the area under the receiver-operating characteristic curve was 0.860 in the Japanese iNPH and 0.849 in the Finnish iNPH cohorts. Immunostaining and in situ hybridization revealed PTPRQ expression in the ependymal cells and choroid plexus. It is highly possible that the elevated PTPRQ levels in the CSF are related to ependymal dysfunction from ventricular expansion. CONCLUSIONS: Cerebrospinal fluid PTPRQ levels indicated the validity of this assay for auxiliary diagnosis of adult chronic hydrocephalus.


Subject(s)
Alzheimer Disease , Hydrocephalus, Normal Pressure , Adult , Amyloid beta-Peptides , Biomarkers , Humans , Protein Tyrosine Phosphatases , Receptor-Like Protein Tyrosine Phosphatases, Class 3
2.
Cancer Radiother ; 23(3): 222-227, 2019 Jun.
Article in English | MEDLINE | ID: mdl-31133512

ABSTRACT

PURPOSE: Chemoradiotherapy and radiotherapy for esophageal cancer sometimes cause esophageal fistulas. Esophageal fistulas often require additional procedures and are associated with a high mortality rate. The present study was conducted to determine the risk factors associated with esophageal fistulas in patients with esophageal cancer. PATIENTS AND METHODS: We reviewed the cases of 206 patients who were treated with definitive radiotherapy for esophageal cancer. The planning dose, which ranged from 44 to 64.8Gy (median: 59.4Gy), was delivered to the primary lesion and regional lymph nodes. Descriptive statistics were calculated, and time-to-event analyses were performed using Cox proportional hazards regression analysis. RESULTS: None of the 68 patients with T1 or T2 esophageal cancer developed esophageal fistulas. Among the 138 patients with T3 or T4 esophageal cancer, esophageal fistulas were detected in 20 (14.5%) patients. Multivariate analysis of the 138 patients with T3 or T4 esophageal cancer revealed low body mass index (BMI) to be an independent risk factor for esophageal fistula formation (P=0.0055). The optimal BMI cut-off value for predicting esophageal fistula formation was 20 kg/m2 (P=0.0121, odds ratio=4.130). CONCLUSION: In patients with esophageal cancer treated with definitive radiotherapy, a BMI below20kg/m2 is a risk factor for esophageal fistula formation. A well-designed randomized controlled trial comparing the incidence of esophageal fistulas between patients with esophageal cancer who do and do not receive nutritional support before radiotherapy is required.


Subject(s)
Esophageal Fistula/etiology , Esophageal Neoplasms/physiopathology , Esophageal Neoplasms/radiotherapy , Nutritional Status , Radiation Injuries/complications , Adult , Aged , Aged, 80 and over , Esophageal Fistula/epidemiology , Female , Humans , Male , Middle Aged , Risk Factors
3.
AJNR Am J Neuroradiol ; 35(9): 1735-9, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24948506

ABSTRACT

BACKGROUND AND PURPOSE: Studies have suggested that arachnoid villi or granulations found in the walls of the cranial dural sinuses, olfactory mucosa, and cranial nerve sheaths function as outlets for intracranial CSF. However, their role as CSF outlets has not yet been verified. Here we show that arachnoid protrusions and contiguous diploic veins provide an alternative drainage route for intracranial CSF. MATERIALS AND METHODS: Four hundred patients with intact skull, dura mater, and dural sinuses underwent MR imaging to explore arachnoids protruding into the skull and diploic veins. Patients with symptoms of increased intracranial pressure or intracranial hypotension were excluded. For 15 patients undergoing craniotomy, both peripheral and diploic venous blood was collected. Albumin and the CSF-specific biomarkers were measured by enzyme-linked immunosorbent assay. RESULTS: With MR imaging, arachnoid protrusions into the skull and contiguous diploic veins were consistently identified throughout the cranium with their characteristic appearance depending on the cranial region. In addition, elevated amounts of prostaglandin D synthase and cystatin C were confirmed in diploic veins compared with peripheral venous blood. CONCLUSIONS: Diploic veins are distributed ubiquitously throughout the cranium. A portion of the intracranial CSF may be drained through arachnoid protrusions and contiguous diploic veins.


Subject(s)
Arachnoid/anatomy & histology , Arachnoid/physiology , Cerebrospinal Fluid/physiology , Veins/anatomy & histology , Veins/physiology , Adult , Aged , Dura Mater/blood supply , Female , Humans , Male , Middle Aged
4.
Clin Neuroradiol ; 23(2): 81-5, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23657430

ABSTRACT

PURPOSE: Primary spinal extradural Ewing's sarcoma (PSEES) or primitive neuroectodermal tumor (PNET) is uncommon. The present study summarizes the magnetic resonance (MR) imaging appearance of PSEES. METHODS: Literature search from 1994 to 2012 with our representative case presentation. RESULTS: Twenty-one patients, 12 males and 9 females, aged 3 weeks to 44 years, were identified. The thoracic spine was most frequently affected, followed by the cervical, cervicothoracic, and thoracolumbar spine. Superior-inferior extension of lesions was three vertebral levels in 7, two in 7, five in 4, four in 1, one in 1 and unknown in 1. PSEESs appeared isointense in 9 cases, hypointense in 2, hyperintense in 1, and no description in 9 on T1-weighted imaging, while hyperintense in 6, hypointense in 3, heterogeneous in 1, and no description in 11 on T2-weighted imaging. Varying enhancement was noted in 13 cases (62 %), with no description of contrast study in the other 8 cases. Dumbbell-shaped configuration of PSEES was found in 5 cases, foraminal widening in 4, and erosions or scalloping of the adjacent vertebral bodies in 4. CONCLUSION: The MR imaging appearance of PSEESs is indistinguishable from other tumors. PSEES should be assumed as the differential diagnosis of spinal extradural tumors in pediatric, adolescent, and young adult patients, and prompt surgical exploration should be performed.


Subject(s)
Cervical Vertebrae/pathology , Lumbar Vertebrae/pathology , Magnetic Resonance Imaging/methods , Sarcoma, Ewing/pathology , Spinal Neoplasms/pathology , Thoracic Vertebrae/pathology , Adolescent , Adult , Child , Child, Preschool , Dura Mater/pathology , Female , Humans , Infant , Infant, Newborn , Male , Young Adult
5.
Eur J Neurol ; 20(2): 236-42, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22672777

ABSTRACT

BACKGROUND: Cognitive impairment is difficult to improve after shunt operation in patients with idiopathic normal pressure hydrocephalus (iNPH). This study aims to identify cerebrospinal fluid (CSF) biomarkers predictive of improvement in cognitive function. METHODS: This study was conducted between January 2008 and December 2010 on consecutive, unselected admissions to our program for the treatment of patients with clinically suspected iNPH. Lumbar CSF concentrations of total tau (Tau), tau phosphorylated at threonine 181 (p-tau), soluble amyloid precursor protein (sAPP), sAPPα, sAPPß, and ß-amyloid(1-42) (Aß42) were analyzed by ELISA. RESULTS: Concentrations of p-tau, sAPP, sAPPα, and sAPPß were strong diagnostic biomarkers for distinguishing between iNPH and Alzheimer's disease (AD). sAPPα exhibited the highest accuracy in differentiating iNPH from patients with AD and normal controls, with an area under the curve value of 0.994. We examined the prognostic value of p-tau and sAPPα for cognition function after surgery. With a cutoff value of 198 ng/ml or less for sAPPα, sensitivity and specificity are 66.7% and 82.9%, respectively, whilst the Mini-Mental State Examination score at 6 months after surgery is expected to be 25 or more. CONCLUSION: Our results show that sAPPα is a suitable biomarker for the diagnosis and prognosis of iNPH.


Subject(s)
Amyloid beta-Protein Precursor/cerebrospinal fluid , Hydrocephalus, Normal Pressure/cerebrospinal fluid , Hydrocephalus, Normal Pressure/diagnosis , Aged , Aged, 80 and over , Alzheimer Disease/cerebrospinal fluid , Alzheimer Disease/diagnosis , Amyloid beta-Peptides/cerebrospinal fluid , Amyloid beta-Peptides/metabolism , Amyloid beta-Protein Precursor/metabolism , Biomarkers/cerebrospinal fluid , Biomarkers/metabolism , Female , Humans , Male , Middle Aged , Peptide Fragments/cerebrospinal fluid , Peptide Fragments/metabolism , Prognosis , Sensitivity and Specificity , Solubility , tau Proteins/cerebrospinal fluid , tau Proteins/metabolism
6.
Acta Neurochir Suppl ; 113: 97-101, 2012.
Article in English | MEDLINE | ID: mdl-22116432

ABSTRACT

OBJECTIVES: We have previously reported that the level of leucine-rich alpha-2-glycoprotein (LRG) expression is specifically increased in cerebrospinal fluid (CSF) of idiopathic normal pressure hydrocephalus (INPH). The objective of this study is to examine the localization of LRG - the cerebral areas where it is expressed. METHOD: The histological sections of autopsied brain specimens from ten subjects, five adult cases (mean age 43.6 years; range 34-50 years) and five senile cases (mean age 76.0 years; range 67-88 years) were prepared, multistained with antibodies against human LRG, glial fibrillary acidic protein (GFAP), CD31, and aquaporin-4 (AQP4), and reviewed for the expression sites of LRG. RESULTS: Immunostains of GFAP and LRG were compared in standard brain specimens from elderly patients. The results indicated that LRG is distributed throughout the entire brain, with especially high expression in the deep cerebral cortex. In addition, the cells that express LRG showed similar morphology to astrocytes. Double staining of CD31 and LRG revealed a significant expression of LRG in the pericapillary regions. The expression was observed in resident astrocytes, as well as in the capillary vessel to which astrocytic processes grow and adhere. When age-related comparisons were made between senile and adult specimens, LRG expression increased with age. CONCLUSION: LRG expression in resident astrocytes increased with age.


Subject(s)
Brain/metabolism , Gene Expression Regulation , Glycoproteins/metabolism , Adult , Age Factors , Aged , Aged, 80 and over , Aquaporin 4/metabolism , Basic Helix-Loop-Helix Transcription Factors/metabolism , Female , Glial Fibrillary Acidic Protein/metabolism , Glucose Transporter Type 5/metabolism , Glycoproteins/genetics , Humans , Male , Middle Aged , Nerve Tissue Proteins/metabolism , Oligodendrocyte Transcription Factor 2 , Platelet Endothelial Cell Adhesion Molecule-1/metabolism , RNA, Messenger/metabolism
7.
Int J Gynecol Cancer ; 16(3): 1094-100, 2006.
Article in English | MEDLINE | ID: mdl-16803491

ABSTRACT

The purpose of this study was to determine the pretreatment serum squamous cell carcinoma antigen (SCC-ag) level as a generally applicable measurement in predicting and estimating the treatment outcome of patients with locally advanced SCC of the cervix. Three hundred fifty-two patients with stage IIB-IVA SCC of the cervix were managed with both external irradiation and high-dose rate intracavitary brachytherapy. A significantly higher median SCC-ag was seen in association with increasing stage, tumor size, and lymph node involvement. The difference in disease-free survival (DFS) between stages IIB and III patients was not statistically significant with SCC-ag level <2 ng/mL. In multivariate analysis, median SCC-ag level (> or =6.0 ng/mL) and lymph node metastases had significant independent effects on absolute survival and DFS. A direct linear relationship (y=-2.932x+ 84.896) existed between the median SCC-ag of groups distributed by pretreatment prognostic factors and the 5-year DFS rate. The 5-year DFS rate as a function of SCC-ag level defined by cervix size, lymph node status, and hydronephrosis was obtained from a formula combining risk scores and the baseline survival function. From the obtained formulas, we can objectively estimate the treatment outcome in patients with locally advanced squamous cell cervical cancer.


Subject(s)
Antigens, Neoplasm/blood , Biomarkers, Tumor/blood , Carcinoma, Squamous Cell/immunology , Carcinoma, Squamous Cell/radiotherapy , Serpins/blood , Uterine Cervical Neoplasms/immunology , Adult , Aged , Aged, 80 and over , Brachytherapy/methods , Carcinoma, Squamous Cell/mortality , Disease-Free Survival , Female , Humans , Middle Aged , Neoplasm Invasiveness/diagnosis , Neoplasm Recurrence, Local/radiotherapy , Predictive Value of Tests , Prognosis , Retrospective Studies , Survival Analysis , Treatment Outcome , Uterine Cervical Neoplasms/mortality , Uterine Cervical Neoplasms/radiotherapy
8.
Int J Gynecol Cancer ; 15(4): 630-8, 2005.
Article in English | MEDLINE | ID: mdl-16014117

ABSTRACT

The objective of this study was to examine the clinical benefits of routine squamous cell carcinoma antigen (SCC-ag) monitoring of patients with locally advanced cervical cancer. Recurrent disease occurred in 99 uterine cervical cancer patients with elevated pretreatment SCC-ag before primary radiotherapy. Elevated SCC-ag levels persisted in 23 patients after primary radiotherapy (group 1), and SCC-ag was normalized in 76 patients after primary radiotherapy (group 2). The overall survival (OS) rate was higher for patients with SCC-ag elevation as the first sign than for patients with recurrence predicted by other modalities for group 2 patients (P = 0.033). The prediction of isolated para-aortic node recurrence significantly correlated with SCC-ag elevation as an initial sign (P = 0.001). The SCC-ag level before primary radiotherapy (> or = 10.8 ng/mL) significantly affected recurrence predicted by SCC-ag elevation as an initial sign (P = 0.002). For multivariate analysis, the presence of para-aortic node recurrence was statistically significant in OS (P < 0.0001). Routine SCC-ag monitoring of patients with carcinoma of the uterine cervix can lead to the early diagnosis of isolated para-aortic lymph node recurrence, and prolonged survival can be achieved by applying radiation therapy to the para-aortic region. To reduce the number of patients monitored for SCC-ag, we recommend monitoring group 2 patients with pretreatment SCC-ag level before primary radiotherapy > or = 10.8 ng/mL.


Subject(s)
Antigens, Neoplasm/blood , Biomarkers, Tumor/blood , Carcinoma, Squamous Cell/diagnosis , Carcinoma, Squamous Cell/radiotherapy , Neoplasm Recurrence, Local/diagnosis , Serpins/blood , Uterine Cervical Neoplasms/diagnosis , Uterine Cervical Neoplasms/radiotherapy , Adult , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/pathology , Female , Humans , Middle Aged , Multivariate Analysis , Survival Analysis , Uterine Cervical Neoplasms/pathology
9.
Acta Neurochir Suppl ; 86: 173-5, 2003.
Article in English | MEDLINE | ID: mdl-14753429

ABSTRACT

Focal cerebral ischemia was induced by occlusion of the left middle cerebral artery (MCAO) for 1 and 3 hours in 14 rats. Five sham-operated rats served as controls. Regional cerebral blood flow (rCBF) was assessed by 14C-iodoantipyrine radioluminography. The potassium and phosphorus contents in brain tissue were assessed using energy-dispersive X-ray fluorescence spectrometry. In the inner periphery within the ischemic tissue where rCBF was severely reduced to 6.61 +/- 0.95 ml/100 g/min 1 hour after MCAO, the potassium content decreased slightly to 12.82 +/- 0.15 mg/g. Potassium content decreased further to 10.61 +/- 0.24 mg/g over 3 hours after occlusion, similar to that in the ischemic core. In contrast, in the outer periphery where rCBF was moderately reduced, the potassium fell slightly to 12.78 +/- 0.46 mg/g 3 hours after MCAO. Tissue phosphorus content decreased to 8.28 +/- 0.24 mg/g only in the ischemic core. These findings demonstrate that potassium and phosphorus in brain tissue depend primarily on the extent, magnitude and duration of ischemia. Ion homeostasis of cell membranes may not be completely disturbed in the periphery around ischemic tissue for a short time after the onset of ischemia, even though blood flow is markedly reduced.


Subject(s)
Brain Ischemia/metabolism , Brain/metabolism , Phosphorus/metabolism , Potassium/metabolism , Animals , Brain Ischemia/physiopathology , Cerebrovascular Circulation , Male , Rats , Rats, Sprague-Dawley , Spectrometry, X-Ray Emission , Time Factors , Tissue Distribution
10.
Int J Gynecol Cancer ; 11(1): 61-8, 2001.
Article in English | MEDLINE | ID: mdl-11285035

ABSTRACT

The purpose of this study was to assess the long-term survival, disease control, and complication rates of high dose rate intracavitary brachytherapy (HDR-ICR) alone or combined with external beam irradiation (HDR-ICR + EBRT) in patients with pathologically involved or close surgical margin in the vagina (Group 1) and recurrent lesions in the vaginal cuff (Group 2) following hysterectomy for cervical carcinoma. In Group 1, 10 patients received HDR-ICR only, and 11 patients received HDR-ICR + EBRT with or without paravaginal shielding. In Group 2, 8 patients received HDR-ICR only, and 11 patients received HDR-ICR + EBRT with or without paravaginal shielding. The HDR-ICR dose per fraction planned at the Apical Vaginal Point was 5-6 Gy per week. In Group 1, the 5-year absolute survival rates (AS), disease-free survival rates (DFS), and vaginal control rates (VC) were 81.0%, 76.2%, and 100%, respectively. The 5-year AS was lower in patients with parametrial infiltration or adenocarcinoma. In Group 2, the 5-year AS, DFS, and VC were 73.3%, 77.4% and 88.8%, respectively. The 5-year AS was lower when tumors were larger than 3 cm or infiltrated. Late complications occurred in 10 patients. In all but one patient, the complications were acceptable. All patients with cystitis, ileus, or leg edema received EBRT + HDR-ICR. We recommend a treatment regimen of 25-30 Gy of HDR-ICR alone for Group 1 patients without pathologically high risk of recurrence or Group 2 patients with superficial recurrent lesions, and a treatment regime of 50 Gy whole pelvis EBRT combined with 10-15 Gy HDR-ICR for Group 1 patients with pathologically high risk of recurrence or Group 2 patients with infiltrated recurrent lesions.


Subject(s)
Brachytherapy , Carcinoma/radiotherapy , Neoplasm Recurrence, Local/prevention & control , Uterine Cervical Neoplasms/radiotherapy , Vagina/pathology , Adult , Aged , Aged, 80 and over , Brachytherapy/adverse effects , Carcinoma/pathology , Combined Modality Therapy , Disease-Free Survival , Dose Fractionation, Radiation , Dose-Response Relationship, Radiation , Female , Humans , Hysterectomy , Middle Aged , Neoplasm Recurrence, Local/radiotherapy , Treatment Outcome , Uterine Cervical Neoplasms/pathology
11.
Radiology ; 218(3): 834-9, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11230664

ABSTRACT

PURPOSE: To assess the effectiveness and long-term results of radiation therapy in infants with life- or function-threatening hemangiomas. MATERIALS AND METHODS: Thirteen patients with life- or function-threatening hemangiomas (eight male, five female; age range, 0-8 months; median age, 2 months) were treated with radiation therapy. Life-threatening hemangiomas were treated with five fractions of radiation per week, and function-threatening hemangiomas were treated with two fractions per week. A median dose of 10 Gy was delivered to each hemangioma. The presence of residual hemangiomas, skin changes, functional problems, and growth delay was evaluated. RESULTS: All patients with Kasabach-Merritt syndrome (KMS) showed regression of the hemangioma and an increase in platelet counts to greater than 100,000 per cubic millimeter (1.0 x 10(11) per liter) within 40 days after radiation therapy. The treatment field was inadequate in two patients who required reirradiation or a change of treatment portal. With the exception of the patients with KMS, all but one patient experienced relief from symptoms in 40 days. Severe long-term radiation-related morbidity was noted in one patient who required reirradiation for a relapsed hemangioma. CONCLUSION: Radiation therapy (in doses of < or = 10 Gy in 2-Gy fractions) is indicated for life-threatening hemangiomas and for some function-threatening hemangiomas.


Subject(s)
Hemangioma/radiotherapy , Soft Tissue Neoplasms/radiotherapy , Adolescent , Child , Child, Preschool , Female , Hemangioma/diagnostic imaging , Humans , Infant , Male , Radiography , Retrospective Studies , Soft Tissue Neoplasms/diagnostic imaging , Treatment Outcome
12.
Mol Ther ; 3(2): 139-48, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11237670

ABSTRACT

Cell-mediated gene therapy for visceral lesions of lysosomal storage diseases is promising; however, the treatment of central nervous system (CNS) lesions remains a challenge. In this study, we generated rat amniotic epithelial cells (AEC) that overexpress and secrete human beta-glucuronidase (GUSB) following transduction with an adenoviral vector encoding human GUSB. The AEC were used as donor cells for cell-mediated gene therapy of CNS lesions in mice with mucopolysaccharidosis type VII (MPSVII), a lysosomal storage disorder caused by an inherited deficiency of GUSB activity. After confirmation that the secreted GUSB was taken up mainly via mannose 6-phosphate receptors in primary cultured neurons, the AEC were transplanted into the brains of adult MPSVII mice. Histochemical analysis showed extensive GUSB activity throughout the ipsilateral hemisphere of the recipient brains, and pathological improvement of the lysosomal storage was observed even in regions far from the site of injection. These results suggest that intracerebral transplantation of genetically engineered AEC has therapeutic potential for the treatment of CNS lesions in lysosomal storage disorders.


Subject(s)
Amniotic Fluid/cytology , Brain/metabolism , Epithelial Cells/metabolism , Gene Transfer Techniques , Genetic Therapy/methods , Lysosomes/metabolism , Mucopolysaccharidosis VII/genetics , Mucopolysaccharidosis VII/therapy , Adenoviridae/genetics , Animals , Cells, Cultured , Disease Models, Animal , Genetic Vectors/metabolism , Glucuronidase/genetics , Humans , Mice , Microscopy, Fluorescence , Neurons/metabolism , Rats , Rats, Wistar , Receptor, IGF Type 2/metabolism , Time Factors , Transduction, Genetic , Transplantation
13.
Int J Cancer ; 96 Suppl: 117-24, 2001.
Article in English | MEDLINE | ID: mdl-11992395

ABSTRACT

It is well known that prophylactic cranial irradiation is highly effective in preventing central nervous system (CNS) relapse of acute lymphoblastic leukemia (ALL). Nevertheless, there have been very few reports on the late effects, especially pituitary function and growth, in long-term survivors who were treated with 18 Gy cranial irradiation in childhood. The subjects consisted of 35 children with ALL who were treated with prophylactic 18 Gy cranial irradiation at Kanagawa Children's Medical Center between October 1981 and February 1995. All patients received cranial irradiation after first attaining complete remission with induction chemotherapy, according to the treatment protocols prescribed by the Tokyo Children's Leukemia Study Group (TCLSG) and Tokyo Children's Cancer Study Group (TCCSG). Their ages at the time of cranial irradiation ranged from 2.2-15.0 years (mean 6.8). We evaluated their pituitary functions by measuring their pituitary hormone values 0.7-11.3 years (mean 6.0) after cranial irradiation and their growth by analyzing their height standard deviation score (SDS) at diagnosis of ALL and their final height SDS at the mean follow-up period of 8.2 years after cranial irradiation. Height SDS is defined as the difference between the patient's height and the mean height of their age and sex, divided by the standard deviation of their age and sex. Eight of 35 patients had ALL relapse, involving the bone marrow in seven patients and the CNS in only one. Six of the eight patients with relapse died 1.5-6.6 years after cranial irradiation and the other two patients were salvaged by further intensive therapies. The remaining 27 relapse-free patients have survived for 1.4-15.8 years (mean 10.1) after cranial irradiation. Twenty-six of the 29 survivors are long-term survivors of more than 5 years. Although there was one patient with an abnormal result in each value of growth hormone (GH), adrenocorticotropic hormone (ACTH), and prolactin (PRL), and two patients with abnormal results in thyroid-stimulating hormone (TSH) values, none of the patients had clinical symptoms of pituitary hormone abnormality and none required hormone supplements. The final height SDS decreased significantly compared with the height SDS at diagnosis of ALL in the long-term survivors (P = 0.001) and the height SDS of the patients who had received cranial irradiation at a young age tended to decrease gradually (P = 0.019). However, no patient showed severe growth failure. It is considered that prophylactic 18 Gy cranial irradiation plus chemotherapy for ALL in childhood can effectively prevent CNS relapse and is unlikely to produce clinically significant late effects, although it may cause slight pituitary hormone abnormality.


Subject(s)
Brain/radiation effects , Pituitary Gland/radiation effects , Precursor Cell Lymphoblastic Leukemia-Lymphoma/radiotherapy , Radiotherapy/methods , Adolescent , Body Height , Child , Child, Preschool , Female , Humans , Male , Pituitary Hormones/metabolism , Time Factors , Treatment Outcome
14.
Int J Radiat Oncol Biol Phys ; 40(4): 881-7, 1998 Mar 01.
Article in English | MEDLINE | ID: mdl-9531374

ABSTRACT

PURPOSE: To assess the effectiveness of high-dose rate intracavitary brachytherapy (HDR-ICR) in patients with grade 3 cervical intraepithelial neoplasia (CIN-3) and grade 3 vaginal intraepithelial neoplasia (VAIN-3). METHODS AND MATERIALS: This was a retrospective analysis in 20 patients with CIN-3 (n = 14) or VAIN-3 (n = 6), average age 61.9 years, managed with HDR-ICR at Kanagawa Cancer Center. Two patients with CIN-3 with microinvasive foci and 11 other patients with CIN-3 were treated with HDR-ICR for cervical lesions. Six patients with CIN-3 after hysterectomy received HDR-ICR for recurrent or residual VAIN-3 lesions. One patient received radiation therapy for both CIN-3 and VAIN-3 lesions. All these patients but one were postmenopausal. RESULTS: Seventeen patients were treated with HDR-ICR alone, and three with combined external radiation therapy. The dose was calculated at Point A located 2 cm superior to the external os and 2 cm lateral to the axis of the intrauterine tube for intact uterus. For lesions of the vaginal stump, the dose was calculated at a point 1 cm superior to the vaginal apex or 1 cm beyond vaginal mucosa. In the 14 patients treated for CIN-3 lesions, the mean total dose of HDR-ICR was 26.1 Gy (range 20-30). Six patients received HDR-ICR for VAIN-3 lesions with mean dose of 23.3 Gy (range 15-30). At follow-up (mean 90.5 months; range 13-153), 14 patients were alive and 6 had died owing to nonmalignant intercurrent disease. No patient developed recurrent disease. Rectal bleeding occurred in three patients, but this symptom subsided spontaneously. Moderate and severe vaginal reactions were noted in two patients, in whom the treatment had included the entire vagina. CONCLUSIONS: HDR-ICR can be employed as the primary management strategy for postmenopausal women with CIN-3. In intraepithelial neoplasia involving the vaginal wall after hysterectomy, HDR-ICR should be considered as an alternative to total vaginectomy.


Subject(s)
Brachytherapy/methods , Uterine Cervical Dysplasia/radiotherapy , Uterine Cervical Neoplasms/radiotherapy , Vaginal Neoplasms/radiotherapy , Adult , Aged , Combined Modality Therapy , Female , Humans , Hysterectomy , Middle Aged , Retrospective Studies , Uterine Cervical Neoplasms/pathology , Uterine Cervical Neoplasms/surgery , Vaginal Neoplasms/pathology , Vaginal Neoplasms/surgery , Uterine Cervical Dysplasia/pathology , Uterine Cervical Dysplasia/surgery
15.
J Digit Imaging ; 10(3): 132-6, 1997 Aug.
Article in English | MEDLINE | ID: mdl-9268909

ABSTRACT

The purpose of this study is to determine whether the computed radiography system sensitivity value can be used as an image quality indicator for computed radiography excretory urography with radiation dose reduction. One hundred and twenty-four patients with gynecological malignancies were studied prospectively. Five-minute and 10-minute computed radiographic images of excretory urography were obtained in each patient with different radiation doses (ie, a standard dose image required with screen-film method and a reduced dose one). The images were subjectivity scored by three radiologists without knowledge of the exposure factors or the system sensitivity values. The quality scores of the reduced-dose images used in the five steps were compared with those of the standard dose images (the system sensitivity value was 80 to 120). The images with reduced exposures were arbitrarily divided into five steps according to the system sensitivity value (ie, 150 to 250, 260-400, 410-600, 610-1000, and 1010-1500). There was a gradual degradation of the image quality as the system sensitivity value was increased. In terms of visualization of the bones, the images taken with the system sensitivity values of 150-250 (40%-67% of the standard dose system) showed no statistically significant difference from the standard dose images. As for visualization of the renal pelvic margins, the images taken with the system sensitivity values of 260 to 400 (2%-38% of the standard dose system) showed no statistically significant difference. We conclude that system sensitivity value can be used as a practical though approximate indicator of the image quality.


Subject(s)
Electronic Data Processing , Genital Neoplasms, Female/diagnostic imaging , Radiographic Image Enhancement/methods , Urography/methods , Adult , Aged , Dose-Response Relationship, Radiation , Female , Humans , Middle Aged , Prospective Studies , Sensitivity and Specificity
16.
Neurosci Lett ; 232(1): 53-6, 1997 Aug 22.
Article in English | MEDLINE | ID: mdl-9292890

ABSTRACT

Human amniotic epithelial (HAE) cells have been used for allotransplantation in patients with lysosomal storage disease due to lack of expression of HLA antigens. Previously, we have reported the expression of differentiation markers for both neural stem cells, and neuron and glial cells. In the present study, we investigated the presence of choline acetyltransferase (ChAT) and acetylcholine (ACh) in HAE cells using different experimental approaches. Cultured HAE cells showed strong immunoreactivity against ChAT antibody. ChAT activity in primary cells was 24.9 +/- 8.5 pmol/mg protein/h. Using HPLC with electrochemical detection, ACh was detected in both cell incubation media and cell pellets indicating that these cells synthesize and release ACh in a time-dependent manner. Additional confirmation of this hypothesis was gained from the data obtained from RT-PCR and Western blot analyses which revealed the expression of ChAT mRNA and ChAT protein, respectively, in HAE cells. Results of the present study suggest that HAE cells can possibly be applied for intracerebral allografting to treat neurologic diseases in which cholinergic neurons are damaged.


Subject(s)
Acetylcholine/metabolism , Amniotic Fluid/cytology , Cell Transplantation/methods , Nervous System Diseases/therapy , Antibodies, Monoclonal , Blotting, Western , Choline O-Acetyltransferase/analysis , Choline O-Acetyltransferase/genetics , Choline O-Acetyltransferase/immunology , Cholinergic Fibers/enzymology , Epithelial Cells , Epithelium/enzymology , Gene Expression Regulation, Enzymologic , Humans , Immunohistochemistry , Placenta/cytology , RNA, Messenger/analysis , Transplantation, Homologous
17.
Int J Radiat Oncol Biol Phys ; 37(5): 1071-7, 1997 Mar 15.
Article in English | MEDLINE | ID: mdl-9169815

ABSTRACT

PURPOSE: To define the influence of the tumor size measured by computed tomography (CT) and lymph node involvement detected by CT in patients treated with radiation therapy for Stage IIB-IVA carcinoma of intact uterine cervix. METHODS AND MATERIALS: This was a retrospective analysis of 233 patients with uterine cervical cancer managed with both external irradiation and high-dose-rate intracavitary brachytherapy (HDR-ICR) at Kanagawa Cancer Center. The results were analyzed for the end points of absolute survival (AS), disease-free survival (DFS), pelvic control (PC), and central control (CC). The parameters of stage, CT-measured anterior-posterior (AP) cervix size, and CT-detected lymph node metastases were evaluated using univariate and multivariate analysis. RESULTS: The stage, AP cervix size, and lymph node involvement were significant pretreatment factors in univariate analysis with respect to AS, DFS, PC, and CC. Multivariate analysis confirmed that significant risk was associated with certain prognostic parameters. Those in terms of AS, in order of decreasing significance, were lymph node involvement, AP cervix size, age, and total HDR-ICR dose. When DFS was studied, lymph node involvement and AP cervix size were demonstrated to have a significant effect. Stage and lymph node involvement significantly affected PC. CONCLUSION: Because the International Federation of Gynecological Obstetrics staging system fails to incorporate important prognostic information about tumor volume and lymph node involvement, CT-detected lymph node metastases as well as CT-measured cervix size should be determined as complementary additional prognostic measures.


Subject(s)
Carcinoma/pathology , Carcinoma/radiotherapy , Uterine Cervical Neoplasms/pathology , Uterine Cervical Neoplasms/radiotherapy , Adult , Aged , Aged, 80 and over , Brachytherapy , Carcinoma/diagnostic imaging , Female , Humans , Middle Aged , Multivariate Analysis , Neoplasm Staging , Prognosis , Retrospective Studies , Survival Analysis , Tomography, X-Ray Computed , Uterine Cervical Neoplasms/diagnostic imaging
18.
Int J Radiat Oncol Biol Phys ; 31(4): 725-34, 1995 Feb 15.
Article in English | MEDLINE | ID: mdl-7860383

ABSTRACT

PURPOSE: To examine the incidence of radiation-induced late rectal complications using a rectal reference point in patients with cancer of the uterine cervix. METHODS AND MATERIALS: The subjects were 253 patients with cancer of the cervix who underwent high dose rate intracavitary brachytherapy (HDR-ICR). The rectal point (RP) was defined according to the criteria recommended in the ICRU Report 38. The time-dose factor (TDF) and the biologically effective dose (BED) were calculated as components of the cumulative reference rectal dose using the rectal reference point dose in intracavitary brachytherapy combined with the external whole pelvis dose. RESULTS: Statistical comparison of factors affecting the incidence of late rectal complication was conducted using data for 161 patients. The incidence of late rectal complications in the 161 patients was 9 patients (5.6%) for grade 1, 51 patients (31.7%) for grade 2, 11 patients (6.8%) for grade 3, and 13 patients (8.1%) for grade 4. The TDF and BED values were significantly correlated with the incidence of late rectal complication, and also showed strong correlation (r = 0.976) with each other. Grade 4 rectal complication was not observed in any patients with TDF below 130 or BED below 147. The calculated incidence of complications ranged from 5 to 10% at TDF values from 104 to 124 and at BED values from 119 to 146. CONCLUSION: These data regarding the incidence of rectal complication may be useful in reducing the incidence of late rectal complications arising after HDR-ICR treatment of cervical uterine cancer by adjusting the dose per fraction and number of fractions of HDR-ICR in individual patients and by improving the technique of inserting the intracavitary radiation apparatus.


Subject(s)
Gastrointestinal Hemorrhage/epidemiology , Rectum/radiation effects , Uterine Cervical Neoplasms/radiotherapy , Female , Gastrointestinal Hemorrhage/etiology , Gastrointestinal Hemorrhage/mortality , Humans , Incidence , Intestinal Mucosa/radiation effects , Neoplasm Staging , Radiotherapy Dosage , Rectovaginal Fistula/epidemiology , Rectovaginal Fistula/etiology , Rectovaginal Fistula/mortality , Uterine Cervical Neoplasms/mortality , Uterine Cervical Neoplasms/pathology
19.
Rev Sci Instrum ; 50(10): 1313, 1979 Oct.
Article in English | MEDLINE | ID: mdl-18699384

ABSTRACT

This note describes a control system for maintaining constant humidity by passing a gas through a saturated aqueous solution.

SELECTION OF CITATIONS
SEARCH DETAIL
...